Brussels, 24 July 2020
Breaking down the barriers to gene therapy production
An increasing number of gene therapy treatments for previously unmet indications are entering the clinical trial pathway. However, the global availability and affordability of current and future gene therapy products is threatened by the challenges associates to their manufacture.
Producing viral vectors using conventional technologies presents several limitations including scalability constraints, high manufacturing cost of goods (COGs), as well as a low productivity and reproducibility. In order to overcome these hurdles, manufacturing technologies must be re-designed with the aim of easing scale-up and reducing COGs.
An enhanced and cost-effective viral vector biomanufacturing